A comparative study of immunohistochemical and chromogenic in situ hybridization (CISH) evaluation of HER2 status in breast cancer

被引：0
|
作者：
Lubomirova, Hristova S. [1 ]
Vlahova, I. A. [1 ]
Iliichev, Dikov T. [1 ]
机构：
[1] Med Univ Sofia, Sofia, Bulgaria
来源：
VIRCHOWS ARCHIV | 2009年 / 455卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [31] HER2/neu Testing in Breast Carcinoma. Concordance Study Fluorescent In Situ Hybridization (FISH) vs. Chromogenic In Situ Hybridization (CISH)
    Elavathil, L.
    Dhesy, B.
    Wiernikowski, J.
    Browning, D.
    Akhtar-Danesh, N.
    Hanna, W.
    MODERN PATHOLOGY, 2009, 22 : 38A - 38A
  • [32] HER2 status in breast carcinomas: comparison between silver in situ hybridization, chromogenic in situ hybridization and fluorescence in situ hybridization
    Ali, S. A. Md
    Nurhayati, H. M.
    Munirah, M. A.
    Reena, M. Z.
    Masir, N.
    Chandramaya, S. F.
    Rohaizak, M.
    Asmiati, A.
    Sharifah, N. A.
    Rafie, M. K.
    EJC SUPPLEMENTS, 2010, 8 (05): : 185 - 185
  • [33] Chromogenic in situ hybridization (CISH), a helpful tool for the pathologist to identify HER2/NEU amplification in breast carcinomas.: Comparative study with IHC and FISH
    Ning, EL
    Ronchetti, R
    Torres-Cabala, CA
    Teller, LS
    MODERN PATHOLOGY, 2005, 18 : 40A - 40A
  • [34] Chromogenic in situ hybridization (CISH), a helpful tool for the pathologist to identify HER2/NEU amplification in breast carcinomas. Comparative study with IHC and FISH
    Ning, EMLL
    Ronchetti, R
    Torres-Cabala, CA
    Teller, LS
    Merino, MJ
    LABORATORY INVESTIGATION, 2005, 85 : 40A - 40A
  • [35] Prospective Testing for Her2 Using Simultaneous Immunohistochemistry (IHC) and Chromogenic In Situ Hybridization (CISH)
    De Luca-Johnson, Javier
    Bryant, Britni R. E.
    Mitchell, Jeannette
    Cortright, Valerie
    Weaver, Donald L.
    Goodwin, Andrew
    Harmon, Maureen
    Ambaye, Abiy
    MODERN PATHOLOGY, 2017, 30 : 505A - 505A
  • [36] HER2 status assessment by chromogenic in-situ hybridization (CISH) demonstrates high sensitivity for predicting response to Herceptin®.
    Hofmann, M
    Gaiser, T
    Kneitz, H
    Weng, LP
    Schmidtgen, C
    Gutjahr, TS
    Gross, C
    Henkel, T
    Rueschoff, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S53 - S54
  • [37] Comparison Between Dual- and Single-Probe Chromogenic In Situ Hybridization (CISH) in Assessing HER2 Gene Status of Chinese Breast Cancer Patients
    Nie, Xiu
    He, Jun
    Han, Mark
    Bai, Chenguang
    Bai, Chenguang
    Huang, Tao
    Ni, Canrong
    Yang, Xiuping
    Chen, Jinsu
    Zheng, Weiqiang
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (04) : 672 - 672
  • [38] Prospective Testing for Her2 Using Simultaneous Immunohistochemistry (IHC) and Chromogenic In Situ Hybridization (CISH)
    De Luca-Johnson, Javier
    Bryant, Britni R. E.
    Mitchell, Jeannette
    Cortright, Valerie
    Weaver, Donald L.
    Goodwin, Andrew
    Harmon, Maureen
    Ambaye, Abiy
    LABORATORY INVESTIGATION, 2017, 97 : 505A - 505A
  • [39] Use of chromogepic in-situ hybridization (CISH) in determining Her2 status
    Jundi, M
    Selim, S
    Phillips, S
    Garcia, FU
    MODERN PATHOLOGY, 2003, 16 (01) : 35A - 35A
  • [40] Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status
    Manuelito A Madrid
    Raymundo W Lo
    Breast Cancer Research, 6
12345